There are 412 resources available
1461P - Predictive value of residual FDG-PET metabolic activity in metastatic non-small cell lung cancer (mNSCLC) patients (pts) with long-lasting response to immune checkpoint inhibitors (ICIs)
Presenter: Toublanc Anne-Claire
Session: Poster session 20
1493P - A phase II, multi-center, open-label, dose-optimization study evaluating telomere targeting agent THIO sequenced with cemiplimab in patients with advanced NSCLC: Preliminary results
Presenter: Tomasz Jankowski
Session: Poster session 21
1507TiP - Phase Ib multicenter study of trastuzumab deruxtecan (T-DXd) and immunotherapy with or without chemotherapy in first-line treatment of patients (pts) with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (OE): DESTINY-Lung03
Presenter: David Planchard
Session: Poster session 21
1383P - Efficacy of capmatinib compared to standard of care for German patients with locally advanced or metastatic NSCLC harboring METex14 mutations: Results from the RECAP study
Presenter: Anna Kron
Session: Poster session 20
658MO - Phase I study of SHR-A2009, a HER3-targeted ADC, in advanced solid tumors
Presenter: Yi-Long Wu
Session: Mini oral session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
1323MO - Immune evasion across space and time in patients with lung cancer enrolled in the PEACE autopsy study
Presenter: Sonya Hessey
Session: Mini oral session 2 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
1077TiP - TAK-500 as a single agent and in combination with pembrolizumab in patients (pts) with advanced solid tumors: Rationale and design of a phase I/II study
Presenter: Harshabad Singh
Session: Poster session 19
1357P - Bevacizumab improved prognosis for advanced EGFR mutant lung adenocarcinoma with brain metastasis receiving cerebral radiotherapy
Presenter: YuanLiang Zhou
Session: Poster session 19
2250P - Exploring tumor microenvironment in lung cancer through patient-derived 3D models
Presenter: NORA JUCIUTE
Session: Poster session 07
1334P - Activity of first line immunotherapy or chemo-immunotherapy in advanced NSCLC with SMARCA4 deficiency
Presenter: Alina Grecea
Session: Poster session 19